69,456 results match your criteria Secondary Lung Tumors


Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy.

Radiother Oncol 2019 May 15;134:151-157. Epub 2019 Feb 15.

Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, USA. Electronic address:

Background: Neutrophil-lymphocyte ratio (NLR) has been associated with mortality in several disease sites. We hypothesized that NLR is associated with inferior outcomes in localized non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT).

Methods: We evaluated the association of pre-treatment NLR, obtained within 6 months of starting SBRT, with overall survival, as well as primary tumor, regional, and distant recurrence. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01678140193006
Publisher Site
http://dx.doi.org/10.1016/j.radonc.2019.01.032DOI Listing
May 2019
1 Read

Primary malignant mesothelioma of the diaphragm with liver invasion: A case report and review of literature.

Medicine (Baltimore) 2019 Apr;98(15):e15147

Department of Pathology, The First Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning Province, China.

Rationale: Malignant mesothelioma is a malignant tumor with poor prognosis, which usually originates in the pleura, peritoneum, and pericardial cavity. Mesotheliomas that originate from the diaphragm are very rare. Here, we report a case of primary malignant mesothelioma of the diaphragm with liver invasion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000015147DOI Listing
April 2019
1 Read

Re-expansion pulmonary edema after resection of cerebellar lesion in a patient with bronchial occupying lesion: A case report.

Medicine (Baltimore) 2019 Apr;98(15):e15046

Department of Anesthesiology, Shengjing Hospital Affiliated to China Medical University, Shenyang, China.

Rationale: Re-expansion pulmonary edema (RPE) is a non-cardiogenic pulmonary edema, and is secondary to pulmonary collapse caused due to various reasons. However, RPE is rarely encountered during non-thoracic surgeries and is associated with much higher risk than that occurring in thoracic surgeries.

Patient Concerns: Herein we have reported a case report of a 55-years-old male patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000015046DOI Listing
April 2019
1 Read
5.723 Impact Factor

Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial.

J Thorac Oncol 2019 Apr 9. Epub 2019 Apr 9.

Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Kerpener Str. 62, 50937 Cologne, Germany. Electronic address:

Introduction: ROS1 rearrangements are found in 1% of lung cancer patients. Therapeutic efficacy of crizotinib in this subset has been demonstrated in early phase trials in the US and East Asia. Here we present data on efficacy and safety of a prospective phase 2 trial evaluating crizotinib in European ROS1-positive patients (EUCROSS). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864193027
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2019.03.020DOI Listing
April 2019
13 Reads

Prospective Study of Isolated Recurrent Tumor Re-irradiation With Carbon-Ion Beams.

Front Oncol 2019 27;9:181. Epub 2019 Mar 27.

Gunma University Heavy Ion Medical Center, Maebashi, Japan.

To perform a prospective study to evaluate the efficacy and safety of isolated recurrent tumor re-irradiation with carbon-ion radiotherapy (RT). The inclusion criteria were clinically proven recurrent tumors, measurable by computed tomography or magnetic resonance imaging, patients ≥ 16 years old, performance status scores between 0 and 2, isolated tumor at a previously irradiated site, and a life expectancy > 6 months. The exclusion criteria were tumor invasion into the gastrointestinal tract or a major blood vessel, uncontrolled infection, early recurrence (<3 months), and severe concomitant diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00181DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445888PMC
March 2019
2 Reads

Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy.

Eur Radiol 2019 Apr 8. Epub 2019 Apr 8.

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan.

Percutaneous radiofrequency ablation (RFA), a generally accepted alternative therapy for patients with liver metastases, is a minimally invasive approach with a favorable safety profile and a lower rate of major complications. The use of RFA or combined RFA plus resection can produce total tumor clearance in patients with unresectable liver metastases. However, the relatively high rate of local tumor progression has prevented the widespread use of RFA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-019-06189-6DOI Listing
April 2019
1 Read

Association of Low Body Mass Index With Poor Clinical Outcomes After Resection of Non-small Cell Lung Cancer.

Anticancer Res 2019 Apr;39(4):1987-1996

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Background/aim: This study was performed to evaluate the influence of the body mass index (BMI) on disease-free survival and overall survival (DFS and OS) in patients with resected non-small cell lung cancer (NSCLC).

Patients And Methods: Overall, 546 of 780 (70%) patients with stage I to III NSCLC who underwent surgical resection were randomly selected. The patients were subdivided into three groups: low BMI (<18. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13309DOI Listing
April 2019
1 Read

Time-restricted Feeding Attenuates High-fat Diet-enhanced Spontaneous Metastasis of Lewis Lung Carcinoma in Mice.

Anticancer Res 2019 Apr;39(4):1739-1748

U.S. Department of Agriculture, Agricultural Research Service, Grand Forks Human Nutrition Research Center, Grand Forks, ND, U.S.A.

Background/aim: Obesity is a risk factor for cancer. Disruption of the daily feeding and fasting rhythm can contribute to obesity. This study tested the hypothesis that time-restricted feeding (TRF) attenuates obesity-enhanced metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13280DOI Listing
April 2019
1 Read

Adipose-specific Monocyte Chemotactic Protein-1 Deficiency Reduces Pulmonary Metastasis of Lewis Lung Carcinoma in Mice.

Anticancer Res 2019 Apr;39(4):1729-1738

U.S. Department of Agriculture, Agricultural Research Service, Grand Forks Human Nutrition Research Center, Grand Forks, ND, U.S.A.

Aim: Monocyte chemotactic protein-1 (MCP1) is a potent adipokine. This study tested the hypothesis that adipose-produced MCP1 contributes to metastasis.

Materials And Methods: In a spontaneous metastasis model of Lewis lung carcinoma (LLC), male adipose MCP1-deficient (Mcp1) and wild-type (WT) mice were fed the AIN93G diet or a high-fat diet (HFD) for 11 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13279DOI Listing

Efficacy of carboplatin plus S-1 for the treatment of non-small cell lung cancer: A protocol for a systematic review of randomized controlled trial.

Medicine (Baltimore) 2019 Apr;98(14):e15099

Department of Respiratory Medicine, The Affiliated Hongqi Hospital of Mudanjiang Medical University, Mudanjiang.

Background: Non-small cell lung cancer (NSCLC) is the most common lung cancer. Numerous clinical studies have reported that the combination of carboplatin and S-1 (CS) can be used to treat NSCLC effectively. However, no systematic review has been conducted to assess its efficacy and safety for NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000015099DOI Listing
April 2019
6 Reads

Amyloidosis secondary to intrapulmonary Castleman disease mimicking pulmonary hyalinizing granuloma-like clinical features: A rare case report.

Medicine (Baltimore) 2019 Apr;98(14):e15039

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

Rationale: Amyloidosis secondary to intrapulmonary Castleman disease (CD) is a rare benign disease diagnosed by histopathology. It seems to be associated with chronic inflammation, and large amounts of IL-6 produced in the germinal center of CD may enhance the production of precursor of amyloid.

Patient Concerns: We reported a case of an 18-year-old woman presenting with dry cough and dyspnea on exertion for 6 months and detailed exams revealed multiple pulmonary nodules, positive antinuclear antibodies, hypocomplementemia, and thrombocytopenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000015039DOI Listing
April 2019
2 Reads

Molecular and cellular stratagem of brain metastases associated with melanoma.

Oncol Lett 2019 May 14;17(5):4170-4175. Epub 2019 Jan 14.

Department of Clinical Pharmacy, Dermatopharmacy and Cosmetology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Tumors of the central nervous system are the most prevalent complications of melanoma, especially in the late stage of disease. Melanoma, lung and breast cancer are the leading cause of secondary tumors in the brain, the majority of them having a poor outcome. Brain dissemination is developed in half of stage IV melanomas and these cases can increase up to 75%, having a major impact on the quality of life. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/ol.2019.9933
Publisher Site
http://dx.doi.org/10.3892/ol.2019.9933DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444343PMC
May 2019
3 Reads

Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study.

Cancer Chemother Pharmacol 2019 Apr 1. Epub 2019 Apr 1.

Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, China.

Purpose: There is no standard treatment strategy for patients with extensive-stage small cell lung cancer (SCLC) who have failed two or more prior chemotherapeutic regimens. In this study, we retrospectively evaluated the efficacy and safety of apatinib in patients with extensive-stage SCLC after failure of more than second-line chemotherapy.

Methods: A study group comprised of 22 patients with extensive-stage SCLC after failure of more than two prior chemotherapeutic regimens was given apatinib orally at an initial dose of 500 mg daily until disease progression or unacceptable toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03823-4DOI Listing
April 2019
2 Reads

Stereotactic Radiation Therapy for Renal Cell Carcinoma Brain Metastases in the Tyrosine Kinase Inhibitors Era: Outcomes of 120 Patients.

Clin Genitourin Cancer 2019 Feb 28. Epub 2019 Feb 28.

Radiation Oncology Department, La Pitié-Salpêtrière Universitary Hospital, Paris, France.

Background: The objective of the study was to evaluate the outcomes in terms of efficacy and safety of a large consecutive series of 362 patients with renal cell carcinoma (RCC) brain metastases treated using stereotactic radiosurgery (SRS) in the tyrosine kinase inhibitor (TKI) era.

Patients And Methods: From 2005 to 2015, 362 consecutive patients with brain metastases from RCC were treated using SRS in 1 fraction: 226 metastases (61 patients) using Gamma-Knife at a median of 18 Gy (50% isodose line); 136 metastases (63 patients) using linear accelerator at a median of 16 Gy (70% isodose line). The median patient age was 58 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.02.007DOI Listing
February 2019
1 Read

Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer.

Cancers (Basel) 2019 Mar 28;11(4). Epub 2019 Mar 28.

UOC Oncologia Medica Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Women treated for breast cancer (BC) are at risk of developing secondary tumors, such as lung cancer (LC). Since rare germline variants have been linked to multiple cancer development, we hypothesized that BC survivors might be prone to develop LC as a result of harboring rare variants. Sixty patients with LC with previous BC (the study population; SP) and 53 women with either BC or LC and no secondary cancer (control population; CP) were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11040441DOI Listing

Treatment of uterine high-grade endometrial stromal sarcoma with apatinib combined with chemotherapy: A case report.

Medicine (Baltimore) 2019 Mar;98(13):e15050

Department of Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.

Rationale: The standard treatment for uterine high-grade endometrial stromal sarcoma (HGESS) is chemotherapy after surgery. However, the traditional combination chemotherapy has certain limitation, for example, the cancer cells will quickly become resistant to the chemotherapy drugs. Apatinib is a small-molecule antiangiogenic agent which has shown promising therapeutic effect against diverse tumor, but it still remains unknown whether apatinib has an antitumor effect in patients with endometrial stromal sarcoma (ESS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000015050DOI Listing
March 2019
1 Read

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

Ann Oncol 2019 Mar 27. Epub 2019 Mar 27.

Drug Development Unit Nashville, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.

Background: Preclinical evidence suggests that MEK inhibition promotes accumulation and survival of intratumoral tumor-specific T cells and can synergize with immune checkpoint inhibition. We investigated the safety and clinical activity of combining a MEK inhibitor, cobimetinib, and a PD-L1 inhibitor, atezolizumab, in patients with solid tumors.

Patients And Methods: This phase I/Ib study treated PD-L1/PD-1-naive patients with solid tumors in a dose-escalation stage and then in multiple, indication-specific dose-expansion cohorts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz113DOI Listing
March 2019
1 Read

FBXW2 suppresses migration and invasion of lung cancer cells via promoting β-catenin ubiquitylation and degradation.

Nat Commun 2019 03 27;10(1):1382. Epub 2019 Mar 27.

Cancer Institute of the Second Affiliated Hospital, and Institute of Translational Medicine, Zhejiang University School of Medicine, 310029, Hangzhou, China.

FBXW2 inhibits proliferation of lung cancer cells by targeting SKP2 for degradation. Whether and how FBXW2 regulates tumor invasion and metastasis is previously unknown. Here, we report that FBXW2 is an E3 ligase for β-catenin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-09289-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437151PMC

Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis.

World J Surg Oncol 2019 Mar 27;17(1):59. Epub 2019 Mar 27.

Neuro-oncology Clinic, National Cancer Center, Goyang, Republic of Korea.

Background: Leptomeningeal carcinomatosis (LMC) is frequently associated with hydrocephalus, which quickly devastates the performance of the patient. Cerebrospinal fluid (CSF) shunt is a widely accepted treatment of choice, but the clinical outcomes in patients with LMC are not well studied. This study aimed to examine the efficacy of a CSF shunt in patients with LMC. Read More

View Article

Download full-text PDF

Source
https://wjso.biomedcentral.com/articles/10.1186/s12957-019-1
Publisher Site
http://dx.doi.org/10.1186/s12957-019-1595-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438037PMC
March 2019
6 Reads

Cancer incidence and mortality trends from 2003 to 2014 in Italy.

Tumori 2019 Apr 28;105(2):121-137. Epub 2019 Mar 28.

5 National Center for Disease Prevention and Health Promotion, National Institute of Health, Rome, Italy.

Objective: To evaluate short-term (2003-2014) cancer incidence and mortality trends in Italy.

Methods: Italian Cancer Registries data, available in the AIRTUM database, from 17 out of 20 regions were used. The number of incident cases and deaths were estimated for those registries and those years with incomplete information. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300891619839844DOI Listing
April 2019
1 Read

[FABP5 promotes cell growth, invasion and metastasis in cervical cancer].

Zhonghua Zhong Liu Za Zhi 2019 Mar;41(3):200-207

Department of Obstetrics and Gynecology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510700, China.

To investigate the functions of FABP5 in the carcinogenesis and development of cervical cancer. The expression of FABP5 was detected in several cervical cancer cell lines (C33A, Siha, Caski, HeLa and HCC94), 206 cases of cervical cancer tissues with stage Ⅰa2-Ⅱa2 and 40 cases of normal cervical tissues by real-time PCR and Western blotting. Then, the cells were infected with lentivirus-mediated siRNA-targeting FABP5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-3766.2019.03.009DOI Listing
March 2019
1 Read

Magnetophoretic Delivery of a Tumor-Priming Agent for Chemotherapy of Metastatic Murine Breast Cancer.

Mol Pharm 2019 Apr 10. Epub 2019 Apr 10.

Department of Industrial and Physical Pharmacy , Purdue University , 575 Stadium Mall Drive , West Lafayette , Indiana 47907 , United States.

Tumor microenvironment is a significant physical barrier to the effective delivery of chemotherapy into solid tumors. To overcome this challenge, tumors are pretreated with an agent that reduces cellular and extracellular matrix densities prior to chemotherapy. However, it also comes with a concern that metastasis may increase due to the loss of protective containment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.molpharmaceut.8b01148DOI Listing
April 2019
1 Read

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ()-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).

Front Oncol 2019 11;9:132. Epub 2019 Mar 11.

University of California Davis Comprehensive Cancer Center, Sacramento, CA, United States.

Mesenchymal epidermal transition and vascular endothelial growth factor pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance. We hypothesized that treatment with cabozantinib plus erlotinib in mutation-positive NSCLC following progression on EGFR TKI therapy may allow tumors to overcome this resistance or restore sensitivity to therapy regardless of T790M status. Patients with advanced NSCLC, known mutation and progressive disease on an EGFR TKI immediately prior to enrollment without intervening therapy were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00132DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421302PMC
March 2019
2 Reads

Increased Thioredoxin-1 Expression Promotes Cancer Progression and Predicts Poor Prognosis in Patients with Gastric Cancer.

Oxid Med Cell Longev 2019 18;2019:9291683. Epub 2019 Feb 18.

Central Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.

Background: Thioredoxin-1 (Trx-1) is a small redox protein, which plays an important role in many biological processes. Although increased expression of Trx-1 in various solid tumors has been reported, the prognostic significance and function of Trx-1 in human gastric cancer (GC) are still unclear. Here, we investigated the clinical and prognostic significance of Trx-1 expression and the function and mechanism of Trx-1 in human GC. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/omcl/2019/9291683/
Publisher Site
http://dx.doi.org/10.1155/2019/9291683DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398115PMC
April 2019
9 Reads

[Correlation between Plasma D-dimer Count and Features of
Non-small Cell Lung Cancer].

Zhongguo Fei Ai Za Zhi 2019 Mar;22(3):151-156

Department of Thoracic Surgery, Ningbo No.2 Hospital, Ningbo 315000, China.

Background: More and more patients with small pulmonary nodules (SPN) can be found along with the developing of chest low-dose computed tomography (LDCT). With current examinations not all the SPN can be diagnosed to be benign or malignant and not all the malignant nodules can be diagnosed to be lymphatic metastasis. We need to study the correlation between plasma D-dimer count of patients before surgery with pathology features of non-small cell lung cancer (NSCLC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.03.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441113PMC
March 2019
1 Read

[A Single Center, Retrospective Analysis of Prognosis in Non-small Cell Lung Cancer Patients with Peritoneal Carcinomatosis].

Zhongguo Fei Ai Za Zhi 2019 Mar;22(3):143-150

Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing 100191, China.

Background: Peritoneal carcinomatosis is a rare clinical event in lung cancer and the prognosis is very poor. There are limited data on what factors predict peritoneal progression and affect the outcome. The aim of this study is to investigate investigate the factors associated with peritoneal carcinomatosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.03.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441112PMC
March 2019
1 Read

Robot-assisted radical nephrectomy for primary renal mesenchymal chondrosarcoma: case report and literature review.

Ren Fail 2019 Nov;41(1):98-103

a Department of Urology , The First Affiliated Hospital of Nanchang University , Nanchang , Jiangxi Province , China.

As an extremely rare malignant neoplasm, only 12 mesenchymal chondrosarcoma (MC) arising in kidney have been reported to date. Herein, we reported a case of primary renal MC resected with robot assistance, which has not been reported before. According to the cases reported in English literature, we analyzed the characteristics of this rare malignancy and systematically review its treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0886022X.2019.1583111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442158PMC
November 2019
1 Read

Pulmonary lymphangitis carcinomatosis: systematic review and meta-analysis of case reports, 1970-2018.

Authors:
Monika Klimek

Postgrad Med 2019 Mar 22:1-10. Epub 2019 Mar 22.

a Department of Laboratory Diagnostics , Medical University of Lublin , Lublin , Poland.

Pulmonary lymphangitis carcinomatosis (PLC) is a life-threating complication in patients suffering from malignancies. Misleading and nonspecific symptoms often result in a delayed diagnosis. This review was aimed at evaluating epidemiology, clinical manifestations, and survival of patients with PLC reported in the literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00325481.2019.1595982DOI Listing
March 2019
3 Reads

Recent advances in the molecular landscape of lung neuroendocrine tumors.

Expert Rev Mol Diagn 2019 Apr 27;19(4):281-297. Epub 2019 Mar 27.

p Christian CRUK and NIHR Southamtpon Experimental Cancer Medicine Centre, Faculty of Medicine , University of Southampton , Southampton , UK.

Introduction: Neuroendocrine tumors of the lung (Lung-NETs) make up a heterogenous family of neoplasms showing neuroendocrine differentiation and encompass carcinoids and neuroendocrine carcinomas. On molecular grounds, they considered two completely distinct and separate tumor groups with no overlap of molecular alterations nor common developmental mechanisms. Areas covered: Two perspectives were evaluated based on an extensive review and rethinking of literature: (1) the current classification as an instrument to obtaining clinical and molecular insights into the context of Lung-NETs; and (2) an alternative and innovative interpretation of these tumors, proposing a tripartite separation into early aggressive primary high-grade neuroendocrine tumors (HGNET), differentiating or secondary HGNET, and indolent NET. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737159.2019.1595593DOI Listing
April 2019
6 Reads

The diagnostic value of circulating tumor cells for lung cancer: A systematic review and meta-analysis.

Medicine (Baltimore) 2019 Mar;98(12):e14936

Department of Laboratory Medicine.

Background: Circulating tumor cells (CTCs) have become a potential diagnostic tumor marker and have the potential for wide clinical applications. However, the diagnostic parameters vary among previous studies. A systematic review of the literature and meta-analysis were conducted to assess the diagnostic value of CTCs for lung cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014936DOI Listing
March 2019
5.723 Impact Factor

Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma: A case report.

Medicine (Baltimore) 2019 Mar;98(12):e14821

Department of Respiratory Internal Medicine, Hiroshima University Hospital, Minami-ku, Hiroshima, Japan.

Rationale: The efficacy of direct oral anticoagulants (DOACs) in the treatment and prophylaxis of cancer-related venous thromboembolism (VTE) is reportedly similar to that of heparin. However, the effect of DOACs on the prophylaxis of cancer-related arterial thromboembolism (ATE) remains unclear. To our knowledge, we present the 1st case where cerebral ATE was encountered during edoxaban administration for VTE in a patient with lung adenocarcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014821DOI Listing
March 2019
1 Read

Lymph node metastasis outside of a tumor-bearing lobe in primary lung cancer and the status of interlobar fissures: The necessity for removing lymph nodes from an adjacent lobe.

Medicine (Baltimore) 2019 Mar;98(12):e14800

Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong University.

The new Tumor Node Metastasis staging system does not recognize fissure status with respect to adjacent lobe invasion (ALI) in lung cancer. Furthermore, no specific surgical strategies have been recommended for lymph node dissections around adjacent nontumor-bearing lobes (NTBLs) according to fissure status. Therefore, this study was undertaken to investigate the necessity of removing additional adjacent lobe lymph nodes in patients with nonsmall cell lung cancer (NSCLC) for lesions limited to in the vicinity of the interlobar fissure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014800DOI Listing
March 2019
1 Read

Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors.

Cancer Sci 2019 Mar 19. Epub 2019 Mar 19.

National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.

Blockade of programmed cell death ligand-1 with durvalumab has shown efficacy and safety in large, international studies of patients with advanced solid tumors. A phase 1, non-randomized, open-label multicenter study was initiated to evaluate durvalumab in a Japanese population. The first part of this study used a standard 3 + 3 dose-escalation design to determine the optimal dosing schedule of durvalumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.14003DOI Listing
March 2019
1 Read

Probabilistic independent component analysis of dynamic susceptibility contrast perfusion MRI in metastatic brain tumors.

Cancer Imaging 2019 Mar 18;19(1):14. Epub 2019 Mar 18.

UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, CA, USA.

Purpose: To identify clinically relevant magnetic resonance imaging (MRI) features of different types of metastatic brain lesions, including standard anatomical, diffusion weighted imaging (DWI) and dynamic susceptibility contrast (DSC) perfusion MRI.

Methods: MRI imaging was retrospectively assessed on one hundred and fourteen (N = 114) brain metastases including breast (n = 27), non-small cell lung cancer (NSCLC, n = 43) and 'other' primary tumors (n = 44). Based on 114 patient's MRI scans, a total of 346 individual contrast enhancing tumors were manually segmented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40644-019-0201-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423873PMC
March 2019
2 Reads

ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report.

Medicine (Baltimore) 2019 Mar;98(11):e14826

OrigiMed, Shanghai.

Rationale: The anaplastic lymphoma kinase (ALK) rearrangements represent a subtype of nonsmall-cell lung cancer (NSCLC), and targeting ALK has radically changed the treatment of NSCLC. Crizotinib, as an ALK inhibitor, has been used in the treatment of ALK-rearranged NSCLC for several years and some adverse effects should be given attention.

Patient Concerns: A 64-year-old woman with a no-smoking history visited hospital in November 2016 because of a persistent cough, expectoration, and progressive dysphagia for 2 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014826DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426651PMC
March 2019
1 Read

Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study.

Onco Targets Ther 2019 28;12:1717-1728. Epub 2019 Feb 28.

Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan.

Background: In RADIANT-4, everolimus showed an improvement of 7.1 months in median progression-free survival (PFS) vs placebo among patients with advanced, well-differentiated, nonfunctional neuroendocrine tumors (NETs) of gastrointestinal (GI) or lung origin. The present analysis focuses on the effect of everolimus on the East Asian-subgroup population of the RADIANT-4 study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S182259DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400121PMC
February 2019
1 Read

Large single cutaneous metastasis of colon adenocarcinoma mimicking a squamous cell carcinoma of the skin: A case report.

Int J Surg Case Rep 2019 7;56:96-100. Epub 2019 Mar 7.

Multidisciplinary Department of Medical and Dental Specialties, Università degli Studi della Campania "Luigi Vanvitelli", Plastic Surgery Unit, Naples, Italy.

Introduction: Metastases represent one of the most outstanding characteristics of malignant neoplasms and are relatively rare in the skin, in spite of the great extension of the cutaneous organs. Development of cutaneous metastases from colon cancer is a rare event, usually occurring in widely disseminated disease and commonly leading to a poor prognosis. As to location, cutaneous metastases often favor areas close to the primary malignancy, such as lung cancer and skin metastases on the trunk. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22102612193010
Publisher Site
http://dx.doi.org/10.1016/j.ijscr.2019.02.043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424055PMC
March 2019
9 Reads

Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.

Sci Rep 2019 Mar 12;9(1):4278. Epub 2019 Mar 12.

Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

To summarize the therapeutic effects of PD-1/PD-L1 inhibitors on patients with advanced non-small cell lung cancer (NSCLC) in a real-world setting, we attempted to identify potential molecular biomarkers or clinical factors that reflected the therapeutic effect. The medical records of patients with non-small cell lung cancer who were treated with PD-1/PD-L1 inhibitors were obtained from the outpatient department or inpatient department of Peking Union Medical College Hospital from August 1, 2015, to January 1, 2018. Our follow-up continued until May 1,2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-40748-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414649PMC
March 2019
2 Reads

Radiation-induced angiosarcoma of the parotid gland after postoperative radiotherapy for hypopharyngeal carcinoma.

Auris Nasus Larynx 2019 Mar 5. Epub 2019 Mar 5.

Department of Otolaryngology - Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto City, Kyoto, Japan.

Secondary carcinogenesis within the irradiation range is one of the most severe problems in cancer survivors. A 60-year-old woman developed hypopharyngeal carcinoma, and she received radical surgery and postoperative radiotherapy. Eight years later, brown pigmentation and induration were observed in the left subaural region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anl.2019.02.001DOI Listing
March 2019
1 Read

Overexpression of HIF-2α-Dependent NEAT1 Promotes the Progression of Non-Small Cell Lung Cancer through miR-101-3p/SOX9/Wnt/β-Catenin Signal Pathway.

Cell Physiol Biochem 2019 8;52(3):368-381. Epub 2019 Mar 8.

Department of Medical Safety, Cangzhou Central Hospital, Cangzhou, China.

Background/aims: The present study aimed to explore the function of NEAT1 on non-small cell lung cancer (NSCLC), as well as its underlying mechanisms.

Methods: Quantitative realtime PCR (qRT-PCR) was used to measure NEAT1 expression in NSCLC tissues and cells. MTT assay and transwell assay were performed to detect cell proliferation, migration and invasion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.33594/000000026DOI Listing
March 2019
7 Reads

Analysis of Histological Grade in Resected Lung-invasive Adenocarcinoma.

Anticancer Res 2019 Mar;39(3):1491-1500

Department of Thoracic and Cardiovascular Surgery, Nara Medical University School of Medicine, Kashihara, Japan.

Background/aim: Although the histological grading systems (Grading) with respect to lung adenocarcinoma are defined using architectural approaches in the eighth cancer Tumor, Node, and Metastasis (TNM) Classification, the prognostic value of the architectural subtypes in advanced stages of the disease remains unclear. We aimed to assess which Grading was more suitable as a prognostic factor: i) (conventional) Grading based on differentiation or ii) (new) Grading based on architectural subtypes.

Patients And Methods: We analyzed the outcomes and Gradings of resected 449 patients with adenocarcinoma using receiver operating characteristic (ROC) curves. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13267DOI Listing

Potential Impact of the Interval Between Imaging and Whole-brain Radiotherapy in Patients With Relatively Favorable Survival Prognoses.

Anticancer Res 2019 Mar;39(3):1343-1346

Department of Radiation Oncology, University of Lübeck, Lübeck, Germany

Background/aim: The interval between diagnostic imaging and whole-brain radiotherapy (WBRT) had no significant impact on survival in our previous study of WBRT for brain metastases. Since median survival time was only 2 months, a potentially negative impact by delaying treatment could have been missed. Therefore, we performed an additional analysis of patients surviving at least 4 months following irradiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13247DOI Listing
March 2019
1 Read

Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced Mutation-positive Non-small-cell Lung Cancer.

Anticancer Res 2019 Mar;39(3):1317-1328

Virgen de la Victoria University Hospital, IBIMA, Campus de Teatinos, Málaga, Spain

Aim: To assess the patterns of disease progression in advanced/metastatic epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) on first-line treatment with erlotinib and identify potential prognostic factors for progression-free survival (PFS).

Patients And Methods: Patients with stage IIIB/IV EGFR-mutation-positive NSCLC receiving first-line erlotinib were followed-up until 24 months after the last patient was enrolled or until premature withdrawal for any cause.

Results: A total of 127 evaluable patients were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13244DOI Listing
March 2019
3 Reads

ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin).

Anticancer Res 2019 Mar;39(3):1267-1273

Department of Obstetrics and Gynecology, Marien Hospital Herne, Ruhr-Universität Bochum, Bochum, Germany.

Background: The members of the slit homolog (SLIT) and roundabout homolog (ROBO) families have emerged as important signaling molecules in tumor metastasis. This study analyzed their role in regulating breast cancer (BC) cell motility and chemotaxis and assessed expression of ROBO1 in brain metastases (BMs) of breast, lung, and colon cancer, and in peritoneal metastases (PMs) of ovarian cancer.

Materials And Methods: The BC cell line MDA-MB231 was subjected to scratch, motility, and chemotaxis assays using heparin and a purified recombinant N-terminal SLIT2 fragment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13237DOI Listing
March 2019
2 Reads

The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma.

Tuberc Respir Dis (Seoul) 2018 Dec 20. Epub 2018 Dec 20.

Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.

Background: Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase II clinical study, we investigated the efficacy and safety of a 4-weekly schedule of docetaxel monotherapy, as first-line chemotherapy for advanced squamous cell carcinoma in elderly lung cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4046/trd.2018.0019DOI Listing
December 2018
2 Reads

Lung Adenocarcinoma Metastasis to the Prostate: A Case Report.

Pract Radiat Oncol 2019 03;9(2):77-80

Department of Radiation Oncology, CHUV, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prro.2018.11.010DOI Listing

Alveolar soft part sarcoma metastatic to the breast: a case report.

BMC Surg 2019 Mar 4;19(1):30. Epub 2019 Mar 4.

Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.

Background: Alveolar soft part sarcoma (ASPS) is an extremely rare neoplasm that tends to occur in the lower limbs of children and adolescents. Metastatic breast tumors constitute 0.5-2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12893-019-0494-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399980PMC
March 2019
3 Reads

[Relationship between morphological characteristics and prognosis of non-nasopharyneal EBV-associated carcinoma].

Zhonghua Bing Li Xue Za Zhi 2019 Mar;48(3):209-214

Department of Pathology, Zhejiang Chinese Medical University Affiliated Zhejiang Cancer Hospital, Hangzhou 310022, China.

To analyze the pathological features and their influence on the clinical outcome of non-nasopharyngeal EBV-associated carcinomas. One hundred and twenty cases of non-nasopharyngeal EBV-associated carcinoma confirmed by in situ hybridization were identified at Zhejiang Cancer Hospital from January 1, 2006 to May 1, 2018, and the clinicopathological data were collected and analyzed using Kaplan-Meier survival analysis, Cox univariate and multivariate analysis. One hundred and twenty cases were involved in the study; the male to female ratio was 1∶1; patients' age range was 24 to 89 years (median 50 years). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0529-5807.2019.03.008DOI Listing
March 2019
4 Reads

Tobacco chemical-induced mouse lung adenocarcinoma cell lines pin the prolactin orthologue proliferin as a lung tumour promoter.

Carcinogenesis 2019 Mar 4. Epub 2019 Mar 4.

Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine; University of Patras; Rio, Achaia, Greece.

Lung adenocarcinoma (LADC) is the leading cause of cancer death worldwide. Nevertheless, syngeneic mouse models of the disease are sparse, and cell lines suitable for transplantable and immunocompetent mouse models of LADC remain unmet needs. We established multiple mouse LADC cell lines by repeatedly exposing two mouse strains (FVB, Balb/c) to the tobacco carcinogens urethane or diethylnitrosamine and by culturing out the resulting lung tumors for prolonged periods of time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgz047DOI Listing
March 2019
4 Reads